@whytee, No. Novartis would not have been able to work that out because they left before the Study Completion Date.
IMO the primary reason Novartis left was because their long term focus was on all cause ARDS and our COVID trial did not help over 65s which would be a significant part of the market.
Hints of the study will include an extended course of Rem-L for older patients. Liking that. Figuring out the correct dosage regimen for over 65s will also help us greatly if we wish to expand into all cause ARDS later (and likely a fair amount of off label use for non COVID ARDS if approved for COVID ARDS first).
@whytee, No. Novartis would not have been able to work that out...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |